Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis
Tamás Tornai(University of Debrecen), Mária Papp(University of Debrecen), Dirk Roggenbuck(Brandenburg University of Technology Cottbus-Senftenberg), Dávid Tornai(Beth Israel Deaconess Medical Center), Alajos Pár(University of Debrecen), Gábor Veres(Southwest General Health Center), Rayan Alsulaimani(University of Debrecen), Gabriella Pár(University of Debrecen), Péter Antal‐Szalmás(University of Debrecen), Gary L. Norman(Nova Medical (United States)), Nóra Sipeki(University of Debrecen), István Tornai(University of Debrecen), Ferenç Szalay(University of Debrecen), Kaï Fechner(Euroimmun Medizinische Labordiagnostika (Germany)), Péter L. Lakatos(McGill University)
Cited by 31
Related Papers
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
|Science|2009|1.5k
ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents
|Journal of Pediatric Gastroenterology and Nutrition|2013|1.4k
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
|Journal of Crohn s and Colitis|2014|1.1k
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
|Journal of Crohn s and Colitis|2021|1.1k